In 2015, CHAI began partnering with the American Cancer Society (ACS) to increase access to high-quality and affordable treatment, strengthen health worker capacity, and help governments establish plans to comprehensively manage the disease. In 2017, CHAI and ACS announced a groundbreaking agreement with pharmaceutical manufacturers, which was then expanded in 2020. With individual agreements with Mylan, Novartis, and Pfizer, Inc., the Cancer Access Partnership increases access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. The agreements will result in significant savings on high-quality medicines, including chemotherapy regimens for the three cancers that cause the most deaths in Africa-- breast, cervical, and prostate. Learn more about the partnership here.

We are also working with governments to better understand their cancer treatment needs and expand services, as well as train health workers on effective treatments and diagnosis. We are helping countries to close the gap on cervical cancer, which is almost entirely preventable through vaccination and timely screening, by supporting them to include the HPV vaccine in the regular course of vaccinations that young girls receive.